The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a fast onset of action. Consequently, selatogrel was...
Main Authors: | Martine Baumann, Benoît Lack, Isabelle Guillaumat, Mark J. Murphy, Markus A. Riederer |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-01-01
|
Series: | Platelets |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09537104.2020.1869711 |
Similar Items
-
The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
by: Lydie Crescence, et al.
Published: (2021-11-01) -
Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
by: Chih-hsuan Hsin, et al.
Published: (2023-09-01) -
Tirofiban potentiates agonist-induced platelet activation and degranulation, despite effectively inhibiting aggregation
by: Martina Aguiar Bucsai, et al.
Published: (2022-11-01) -
Adenosine Receptor Agonists Increase the Inhibition of Platelet Function by P2Y<sub>12</sub> Antagonists in a cAMP- and Calcium-Dependent Manner
by: Nina Wolska, et al.
Published: (2020-07-01) -
Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y<sub>12</sub> Receptor Antagonists
by: Nina Wolska, et al.
Published: (2019-12-01)